Knoll Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Knoll Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.09M	Hold	600,400	–	–	2.82%	17
2025 Q4	$7.28M	Hold	600,400	–	–	3.34%	12
2025 Q3	$7.02M	Hold	600,400	–	–	3.76%	11
2025 Q2	$1.86M	Hold	600,400	–	–	1.32%	19
2025 Q1	$4.4M	Hold	600,400	–	–	2.86%	11
2024 Q4	$5.13M	Hold	600,400	–	–	3.3%	9
2024 Q3	$5.22M	Buy	600,400 +400,000	+200%	+$3.3M	2.42%	12
2024 Q2	$1.37M	Hold	200,400	–	–	0.92%	20
2024 Q1	$1.82M	Hold	200,400	–	–	1.13%	19
2023 Q4	$894K	Buy	200,400 +200,000	+50,000%	+$591K	0.74%	29
2023 Q3	$1.26K	Sell	400 -199,600	-100%	-$817K	﹤0.01%	37
2023 Q2	$1.03M	Hold	200,000	–	–	1.25%	14
2023 Q1	$1.5M	Buy	+200,000	New	+$950K	2.32%	10

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Knoll Capital Management's OCUL Position: Q1 2026 in Review

Knoll Capital Management held its Ocular Therapeutix (OCUL) position steady in Q1 2026 at 600,400 shares worth $5.09M. The position accounts for 2.82% of the portfolio, ranked #17.

Knoll Capital Management first reported a position in OCUL in Q1 2023 and has held it in 13 quarters since. The position peaked at $7.28M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Knoll Capital Management held 600,400 shares of Ocular Therapeutix worth $5.09M as of Q1 2026.
Knoll Capital Management left its Ocular Therapeutix share count unchanged in Q1 2026.
Ocular Therapeutix made up 2.82% of Knoll Capital Management's portfolio in Q1 2026, its #17 holding.
Knoll Capital Management first reported a position in Ocular Therapeutix in Q1 2023 and has held it in 13 quarters since.
Knoll Capital Management's Ocular Therapeutix position peaked at $7.28M in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Knoll Capital Management's 13F filing for Q1 2026, filed 15 May 2026.